Shares of Second Sight Medical Products Inc. (NASDAQ:EYES) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Brokers have set a 1-year consensus price objective of $16.00 for the company and are anticipating that the company will post ($0.16) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Second Sight Medical Products an industry rank of 103 out of 265 based on the ratings given to related companies.

A number of research analysts have weighed in on the company. Zacks Investment Research upgraded Second Sight Medical Products from a “sell” rating to a “hold” rating in a report on Wednesday, June 1st. Rodman & Renshaw restated a “buy” rating and issued a $16.00 price objective on shares of Second Sight Medical Products in a report on Tuesday, July 26th.

Several hedge funds and other institutional investors have recently bought and sold shares of EYES. Schwab Charles Investment Management Inc. raised its position in Second Sight Medical Products by 11.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 40,984 shares of the medical device company’s stock valued at $147,000 after buying an additional 4,135 shares in the last quarter. AQR Capital Management LLC bought a new position in Second Sight Medical Products during the second quarter valued at approximately $102,000. State Street Corp raised its position in Second Sight Medical Products by 18.2% in the second quarter. State Street Corp now owns 211,197 shares of the medical device company’s stock valued at $756,000 after buying an additional 32,554 shares in the last quarter. Alliancebernstein L.P. raised its position in Second Sight Medical Products by 20.2% in the second quarter. Alliancebernstein L.P. now owns 33,900 shares of the medical device company’s stock valued at $121,000 after buying an additional 5,700 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. raised its position in Second Sight Medical Products by 16.6% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 352,058 shares of the medical device company’s stock valued at $1,260,000 after buying an additional 50,092 shares in the last quarter. Institutional investors and hedge funds own 6.88% of the company’s stock.

Shares of Second Sight Medical Products (NASDAQ:EYES) opened at 3.22 on Thursday. The company has a 50-day moving average of $3.60 and a 200-day moving average of $4.19. The stock’s market capitalization is $135.88 million. Second Sight Medical Products has a 1-year low of $3.17 and a 1-year high of $9.80.

Second Sight Medical Products (NASDAQ:EYES) last announced its quarterly earnings data on Thursday, July 28th. The medical device company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by $0.02. The firm earned $1.04 million during the quarter, compared to analysts’ expectations of $2.66 million. Second Sight Medical Products had a negative net margin of 366.25% and a negative return on equity of 103.44%. The company’s revenue for the quarter was down 63.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.12) EPS. On average, equities research analysts expect that Second Sight Medical Products will post ($0.62) EPS for the current fiscal year.

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

5 Day Chart for NASDAQ:EYES

Get a free copy of the Zacks research report on Second Sight Medical Products (EYES)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Second Sight Medical Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.